| Name | HG7MY8V9AA |
|---|---|
| Synonyms |
[(4S)-8-{2-[6-(Methylamino)-2-pyridinyl]ethoxy}-3-oxo-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepin-4-yl]acetic acid
1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-, (4S)- [(4S)-8-{2-[6-(methylamino)pyridin-2-yl]ethoxy}-3-oxo-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepin-4-yl]acetic acid HG7MY8V9AA SB273005 |
| Description | SB-273005 is a potent nonpeptide and orally active integrin antagonist with Kis of 1.2 nM and 0.3 nM for αvβ3 receptor and αvβ5 receptor, respectively[1]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 662.9±55.0 °C at 760 mmHg |
| Molecular Formula | C22H24F3N3O4 |
| Molecular Weight | 451.44 |
| Flash Point | 354.7±31.5 °C |
| Exact Mass | 451.171906 |
| LogP | 3.16 |
| Vapour Pressure | 0.0±2.1 mmHg at 25°C |
| Index of Refraction | 1.563 |
| Storage condition | -20℃ |